miPlan: A Trial of miPlan Intervention vs. Standard of Care
24. august 2016 oppdatert av: University of Chicago
miPlan: A Randomized Controlled Trial of miPlan Intervention vs. Standard of Care
Using our experience in digital media, behavior theory, client-centered interventions, and family planning, we have prototyped a digital application ("app")-miPlan-to be used in the clinic waiting room prior to a contraceptive visit.
The goal of this research is to refine the app and conduct a randomized controlled trial of the miPlan intervention vs. standard care.
The aim of this study is to understand miPlan's impact.
The primary outcome is LARC uptake at clinic discharge.
The secondary outcomes are contraceptive use at discharge, self-efficacy and decisional balance for highly effective contraception post-app use, contraceptive satisfaction, and intention to continue method use.
The research will consist of baseline activities as well as a three-month follow-up call.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Using our experience in digital media, behavior theory, client-centered interventions, and family planning, we have prototyped a digital application ("app")-miPlan-to be used in the clinic waiting room prior to a contraceptive visit.
The goal of this research is to refine the app and conduct a randomized controlled trial of the miPlan intervention vs. standard care contraceptive counseling.
The aim of this study is to understand miPlan's impact in terms of contraceptive knowledge, intentions and behaviors.
The primary outcome is LARC uptake, which will be measured via chart review at clinic discharge, i.e. immediately following a patient's family planning visit.
The secondary outcomes are contraceptive use at discharge (measured via chart review immediately following patient's family planning visit), self-efficacy and decisional balance (both measured via adapted validated scales for each) for highly effective contraception post-app use (measured immediately following intervention and prior to contraceptive counseling session), contraceptive satisfaction (measured at 3 months post baseline), and intention to continue method use (measured at 3 months post baseline).
The research will consist of baseline activities as well as a three-month follow-up call.
Studietype
Intervensjonell
Registrering (Faktiske)
225
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60636
- Planned Parenthood Illinois, Englewood Health Center
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
15 år til 29 år (Barn, Voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Hunn
Beskrivelse
Inclusion Criteria:
- African American or Latina female and sexually active with a male partner(s) within the past 6 months,
- age 15 to 29 years
- present for contraception initiation
- English speaking
Exclusion Criteria:
- not currently pregnant or intending pregnancy within the next 6 months
- and not currently using LARC
- not highly intending LARC at enrollment
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Intervention
After completing baseline the baseline questionnaire, women randomized to the intervention group will receive an iPad, along with a brief tutorial on iPad navigation, and use the miPlan app for up to 15 minutes.
They will complete a post-intervention survey before proceeding to standard of care contraceptive counseling.
|
miPlan mobile contraceptive counseling waiting room app intervention
|
|
Ingen inngripen: Control
After completing baseline the baseline questionnaire, women randomized to the control arm will proceed to standard of care contraceptive counseling.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
LARC uptake
Tidsramme: at time of intervention (baseline (0 weeks)
|
uptake of the implant or IUD at time of intervention (measured via contraceptive method choice and delivery by checkbox)
|
at time of intervention (baseline (0 weeks)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
contraceptive use
Tidsramme: at time of intervention (baseline (0 weeks))
|
use of contraceptive methods at time of intervention (measured via contraceptive method choice and delivery by checkbox)
|
at time of intervention (baseline (0 weeks))
|
|
change in self-efficacy for contraception at 12 weeks
Tidsramme: baseline (0 weeks) and 12 weeks
|
change in self efficacy for contraceptive method use (measured via validated 5-item attitudinal scale by Galavotti et al 1995) from baseline to 12 weeks
|
baseline (0 weeks) and 12 weeks
|
|
change in decisional balance for highly effective methods at 12 weeks
Tidsramme: baseline (0 weeks) and 12 weeks
|
change in decisional balance for highly effective methods (measured via validated 10-item attitudinal scale by Galavotti et al 1995) from baseline to 12 weeks
|
baseline (0 weeks) and 12 weeks
|
|
contraceptive satisfaction
Tidsramme: 12 weeks post-enrollment
|
satisfaction with contraceptive method choice (measured by 4-point Likert scale)
|
12 weeks post-enrollment
|
|
intention to continue method use
Tidsramme: 12 weeks post enrollment
|
intention to continue contraceptive method use (measured dichotomously)
|
12 weeks post enrollment
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Melissa Gilliam, MD, MPH, University of Chicago, Dept. of OBGYN
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. februar 2015
Primær fullføring (Faktiske)
1. juni 2016
Studiet fullført (Faktiske)
1. august 2016
Datoer for studieregistrering
Først innsendt
16. februar 2015
Først innsendt som oppfylte QC-kriteriene
17. mars 2015
Først lagt ut (Anslag)
24. mars 2015
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
25. august 2016
Siste oppdatering sendt inn som oppfylte QC-kriteriene
24. august 2016
Sist bekreftet
1. august 2016
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 14-0599
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .